• Profile
Close

Landmark finding: First diabetes drug useful in heart failure

M3 India Newsdesk Sep 28, 2021

The EMPEROR-Preserved study revealed- for the first time that the SGLT2 inhibitor empagliflozin improves clinical outcomes in patients with heart failure (HF) with preserved ejection fraction.


The empagliflozin study included individuals with HFpEF who were either diabetic or did not have diabetes. In the EMPEROR-Reduced study, empagliflozin also improved clinical outcomes in individuals with HF and reduced ejection fraction, with or without diabetes.

These findings are the first to demonstrate an unambiguous advantage of any medication on major heart failure outcomes in individuals with heart failure but maintained ejection fraction. The New England Journal of Medicine published the EMPEROR-Preserved study.


Findings from EMPEROR-Preserved

Anker and colleagues allocated a total of 5,988 patients (mean age, 72 years; 45% female; 49% with diabetes) who had New York Heart Association (NYHA) class II to IV congestive heart failure (CHF) with an ejection fraction (EF) over 40% to take empagliflozin 10 mg daily or receive a placebo. The main outcome measure was mortality due to CV disease or hospitalisation for HF.

During a median follow-up of 26.2 months, the primary outcome occurred in 13.8 per cent of the empagliflozin group versus 17.1 per cent of the placebo group (HR = 0.79; 95 per cent confidence interval [CI], 0.69-0.9; P.0003; number needed to treat to prevent one event = 31), driven by HF hospitalisation (HR = 0.71; 95 per cent CI, 0.6-0.83).

The findings were consistent in both diabetic and non-diabetic individuals. He noted that the findings did not vary by EF (41% to 49%, 50% to 59%, or 60% or above), with a P-value for the trend of.21. The primary-secondary endpoint, total hospitalisations for HF (first and subsequent), was lower in the empagliflozin group (HR = 0.73; 95 per cent CI, 0.61-0.88; P.0009), according to Anker.

According to the findings, the second secondary outcome, the slope of the decrease in glomerular filtration rate over time, similarly preferred empagliflozin (difference, 1.36 mL/min/1.73m2 per year; P.0001). CV mortality was decreased by 9% in the empagliflozin group, but the reduction was not statistically significant (HR = 0.91; 95 per cent confidence interval [CI], 0.76-1.09).

There was no difference in all-cause mortality between the groups (HR = 1; 95 per cent CI, 0.87-1.15). Empagliflozin group had a greater incidence of simple vaginal and urinary tract infections as well as hypotension than the placebo group, but there was no difference in amputation, ketoacidosis, or hypoglycaemia.


HFpEF's practical problems

The success of the EMPEROR-Preserved trial follows years of inability to demonstrate statistically significant improvements in clinical outcomes in patients with HFpEF treated with other agents, including the CHARM-Preserved trial of candesartan, the PEP-CHF trial of perindopril, the I-PRESERVE trial of irbesartan, the TOPCAT trial of spironolactone, and the PARAGON-HF trial of sacubitril (Entresto, Novartis).

Only now can we declare that empagliflozin has the potential to enhance [important clinical outcomes] in heart failure with maintained ejection fraction for the first time. It was a clinically significant and significant decrease.

These findings indicate that empagliflozin has a lesser protective impact on the kidneys in individuals with heart failure who have a preserved ejection fraction than in those with a decreased ejection fraction. According to these results, it seems probable that renal protection is not the primary mechanism by which empagliflozin reduces heart failure hospitalisation.

The EMPEROR-Preserved study indicates "a significant victory against a previously difficult medical disease." Finally, given the scarcity of treatment alternatives for patients with heart failure and preserved ejection fraction, the EMPEROR-Preserved study should lead to a shift in clinical practice.

Numerous medications have been shown to be ineffective in this group, although two of them, spironolactone and sacubitril/valsartan, were borderline and showed some promise. Spironolactone was shown to be ineffective in the TOPCAT study. Sacubitril/valsartan was shown to be neutral in the PARAGON-HF study, with a P-value of.059. However, the FDA recently authorised this medication for certain patients with HFpEF owing to a lack of alternative choices.

This is a significant improvement over five years ago when there were no particular treatments for HFpEF and we concentrated on comorbidities such as hypertension, atrial fibrillation, and ischaemic heart disease. Now, we have two distinct classes of treatments that are directed particularly at individuals with HFpEF and should have a significant effect on the disease's course and burden.


Finally, in the research of HFpEF, we have a medication that is both efficacious and safe and improves clinical outcomes. We are now getting some good news for people with HFpEF after many years of waiting. The cardiology community is overcome with pleasure and relief. This is definitely groundbreaking. The consequence is that empagliflozin will almost certainly be one of the first treatments used to keep patients with HFpEF out of the hospital and avoid CV events.


Click here to see references

 

Disclaimer- The views and opinions expressed in this article are those of the author's and do not necessarily reflect the official policy or position of M3 India.

The author is a practising super specialist from New Delhi.
 

Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay